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New technologies, such as metabolomics, can address chemical grouping and read across from a bio-
logical perspective. In a virtual case study, we selected MCPP as target substance and MCPA and 2,4-DP as
source substances with the goal to waive a 90-day study with MCPP. In order to develop a convincing
case to show how biological data can substantiate read across, we used metabolomics on blood samples
from the 28-day studies to show the qualitative and quantitative similarity of the substances. The 28-day
metabolome evaluation of source substances and the target substance indicate liver and kidneys as target
organs. 2,4-DP was identiﬁed as the best source substance. Using the information of the 90-day 2,4-DP
study, we predicted MCPP's toxicity proﬁle at 2500 ppm: reduced food consumption and body weight
gain, liver and kidney weight increases with clinical-pathology changes and a moderate red blood cell
parameter reduction. NOEL prediction for MCPP was below that of 2,4-DP (<500 ppm), and similar to
that of MCPA (150 ppm). Qualitatively, these predictions are comparable to the results of the real MCPP
90-day study in rats (reduced food consumption and body weight gain, weight increases and clinical-
pathology changes in liver and kidneys, reduced red blood cells values). Quantitatively, the predicted
NOAEL (150 ppm) is similar to the actual study (NOEL ¼ 75 ppm, NOAEL  500 ppm). Thus, the 90-day
rat toxicity study of MCPP could have been waived and substituted by the 90-day results of 2,4-DP by
using metabolome data of 28 day studies.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The information requirements according to the REACH legisla-
tion, and the number of chemicals involved, lead to a very signiﬁ-
cant increase of animal testing. The REACH legislation, in principle
notes that animal testing should be the last resort and promotes the
development and use of alternative methods. However, with the
exception of some less complex studies (e.g. skin and eye irritation),
very little progress has been made to have validated and regulatory
acceptable alternative methods in place for REACH testing (Hoefer
et al., 2004; Hartung and Leist, 2008). Grouping of chemicals and
subsequent read across from data rich chemicals belonging to the
group is probably the most efﬁcient way to provide the required
safety information, while keeping the amount of animal testing to
an absolute minimum. The big question here is the quality of the
grouping process. Read-across entails the use of relevant. van Ravenzwaay).
r Inc. This is an open access articleinformation from analogous substances (the ‘source’ information)
to predict properties for the ‘target’ substance(s) under consider-
ation. Grouping and read-across may be based purely on structural
similarity, however, with some risk of error. It would therefore
seem prudent to include and take into account some biological data
in the grouping process, whenever possible (van Ravenzwaay et al.,
2012). These may come from in vitro studies, or could be derived
from a limited number of base set animal studies. Omics technol-
ogies could serve as an important tool to enhance the quality and
quantity of data obtained during regulatory toxicity testing
(ECETOC, 2008; ECETOC, 2010).
ECHA has the obligation to evaluate if submitted read-across
cases are sufﬁciently convincing to substitute these for standard
tests. In response to this challenge ECHA developed and published
the Read-Across Assessment Framework (RAAF) http://echa.
europa.eu/documents/10162/13628/raaf_en.pdf. In this framework
read-across approaches are assessed through the use of different
scenarios and the quality of the case is consistently evaluated based
on a number of predeﬁned criteria. If supporting evidence is pro-
vided for a read-across case then this may be taken into accountunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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approaches and methodologies for investigating properties of
chemicals have been developed over the past years. To assess the
value of these new approach methodologies (NAMs), ECHA orga-
nized a workshop in Helsinki in April 2016 called “Topical Scientiﬁc
Workshop on New Approach Methodologies in Regulatory Sci-
ence”. The present paper was prepared as a case study for this
workshop using metabolomics as a NAM to support read across.
In this paper we describe how metabolomics, can be used to
address chemical grouping and read across from a biological
perspective. The goal was to provide a convincing case to waive a
90-day rat study for the target substance MCPP (also referred to as
Mecoprop or Mecoprop-p). Two other phenoxy-herbicides, MCPA
and 2,4-DP (also referred to as Dichlorprop or Dichlorprop-P) were
selected as source substances. It should be noted here that one of
the requirements to serve as a case study was a substantial
chemical similarity as speciﬁed in the RAAF. MCPP and 2,4-DP are
phenoxypropionic acids and have a chiral centrum. In the past,
these compounds were produced as racemic (50:50) mixtures of
the two enantiomers. Since the 1990's the production has been
modiﬁed to only produce one enantiomer (in documents generally
speciﬁed by the addition of -p to the name of the compounds, e.g.
mecoprop-p) which has the highest herbicidal activity. As the
herbicidal activity is related to a plant speciﬁc receptor, not present
in animals, the toxicity of racemic mixture and single enantiomer
was shown to be identical. The modern toxicological package for
both compounds has been generated in the 1990's and 2000's with
the single enantiomer. The metabolome studies presented here
were also performed with the single “ep” isomer. It should also be
noted, that there are more phenoxy herbicides than the ones used
for this case study, in particular 2,4-D, these, however were not
included here, because of a lack of appropriate metabolomics data.
Within the context of ECHA's RAAF we work with the category
approach, scenario 4 or 6. This scenario covers the category
approach for which the hypothesis is based on different com-
pounds, which have the same type of effect(s). For the REACH in-
formation requirement under consideration, the effects obtained in
studies conducted with different source substances are used to
predict the effects that would be observed in a studywith the target
substance if it were to be conducted. Concerning the strength of the
effect (i.e. the major differences between cat 4 and 6) wewould like
the data to speak for itself and make a reasonable conclusion when
all data are considered together. The overall purpose of this paper is
to demonstrate the possibilities to assess toxicity by means of
multi-parameter ‘omics sciences’, in this case particularly
metabolomics.
For the read across case, the situation is as follows: there is an
adequate 28-day rat study with MCPA, but only limited 28-day
information for 2,4-DP. For all three substances, metabolome data
from 28-day studies are available. The metabolome information is
used for two purposes: 1) to predict the toxicological proﬁle of each
of the compounds, and 2) to compare the similarity of the metab-
olome of the source substances with the target substance and select
the most appropriate one, to make a prediction of the 90-day
toxicity in rats of the target compound. For both source sub-
stances 90-day studies are available. Finally, we compare the pre-
dicted outcome for the target substance with the real outcome.
1.1. Identity of the target substance
Structural information as well as phys-chem data on the target
substance MCPP as well as on the source substances MCPA and 2,4-
DP are depicted in Fig. 1.
The target substance and source substances are structurally
similar. The target substance MCPP is a phenoxypropionic acid, andas such comparable with phenoxypropionic acid 2,4-DP. The target
substance has amethyl and chlorine substituent in the 2,4-position,
and this part of the molecule is thus most similar with MCPA. The
structural similarities of the compounds can be quantiﬁed by
Tanimoto Scores (Fig. 2).
The different parameters of acute toxicity for the target sub-
stance and the source substances are listed in Table 1.
1.2. Conclusion
Acute Toxicity: the acute toxicity of the target substance and the
source substances are comparable.
Mutagenicity: overall there are no concerns about the geno-
toxicity of the target and source compounds.
2. Absorption, distribution, metabolism & excretion
Absorption, distribution, metabolism and excretion, in short
ADME, parameters are available for all three substances (MCPP was
reviewed by California Environmental Protection Agency, 1999;
MCPA was reviewed by JMPR, 2012; 2,4-DP was reviewed by
California Environmental Protection Agency, 2002). The ADME re-
sults are summarized in Table 2. For all substances 14C e phenyl
labelled test substance was administered once by gavage as an
aqueous CMC suspension to rats. Animals were maintained in
metabolism cages. Studies were basically performed according to
the respective OECD and US_EPA test guidelines for kinetics and
metabolism.
Overall, bioavailability for target and source substances is high
(>90% at low dose levels), to a somewhat lesser extent at higher
dose levels. For all substances there is rapid elimination predomi-
nantly through the urine (low dose levels 80e90%) at high dose
levels to a slightly lesser extent. Fecal elimination accounts for ca.
10% or less at low dose levels, and increases up to ca. 20% at high
dose levels. Reduced urinary excretion and increased fecal excre-
tion at high dose levels indicate a slightly reduced bioavailability at
high dose levels. There is no elimination through the expired air.
Fast elimination is reﬂected in relatively short, less than 8 h, and
comparable half-lives. The unchanged parent compound is for all
three substances by far the major component in the blood. Meta-
bolism is limited to the production of one or a few minor metab-
olites (e.g. for MCPA: hydroxylation of the methyl group of the
alcohol (HMCPA), followed by a second hydroxylation to form the
acid (CCPA)), some of which have been tested for systemic toxicity
and shown to be less toxic (van Ravenzwaay et al., 2005). There
were no major differences between male and female animals. In
conclusion, the ADME properties of the target and sources sub-
stances are substantially similar.
3. Twenty-eight-Day toxicity studies
There are only few 28-day toxicity studies available in the public
literature and most of these studies have been performed at rela-
tively low dose levels. Hence, the toxicological proﬁles following 28
days of compound administration are not very well deﬁned (with
the exception of MCPA). The ﬁndings of these studies have been
summarized in Table 3.
3.1. MCPA (van Ravenzwaay et al., 2005)
Five male and ﬁve femaleWistar rats received MCPA at a dietary
concentration of 2000 ppm for four weeks, with examinations ac-
cording to OECD guideline 407. Test substance intake was 166 and
172 mg/kg body weight/day for males and females respectively.
MCPA caused no clinical signs either during the study or in the





Fig. 2. Tanimoto scores for MCPP, 2,4-DP and MCPA using the MACCS keys software.
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consumptionwas signiﬁcantly lower throughout the study inmales
and in females during the last week of treatment. The same was
found regarding body weights and body weight changes. There
were no statistically signiﬁcant changes in hematological parame-
ters. Clinical chemistry revealed several changes with relativelysmall magnitude. These included higher alanine aminotransferase
activity and magnesium levels and lower bilirubin, glucose and
albumin levels in females and higher creatinine and lower glucose
levels in males. Urinalysis revealed a slightly increased urobili-
nogen excretion in males and females signiﬁcant only for females.
An increased number of degenerated transitional epithelial kidney
Table 1
Summary of acute toxicity of the two source substances MCPP and 2,4-DP and the target substance MCPP. Findings are based on the toxicological studies described in USA- EPA
(2007a) and California Environmental Protection Agency (1999) for MCPP, USA-EPA (2007b) for 2,4-DP and USA-EPA (2004) for MCPA.
MCPP 2,4-DP MCPA
Acute oral toxicity (mg/kg bw) LD50 ¼ 775 LD50 ¼ 567 LD50 ¼ 765
Acute inhalation toxicity (mg/l air) LC50 > 5.6 LC50 > 2.3 LC50 > 6.3
Acute dermal toxicity (mg/kg bw) LD50 > 2000 LD50 > 2000 LD50 > 2000
Skin irritation Irritant Irritant Slightly irritant (no classiﬁcation)
Eye irritation Strongly irritant Strongly irritant Strongly irritant
Skin sensitization Non sensitizer Non sensitizer Non sensitizer
Mutagenicity Overall negative Overall negative Overall negative
Table 2
Summary of ADME data of the two source substances MCPA and 2,4-DP and the target substance MCPP. Findings are based on the toxicological studies described in USA- EPA
(2007a) and California Environmental Protection Agency (1999) for MCPP, USA-EPA (2007b) for 2,4-DP and USA-EPA (2004) for MCPA.
MCPP 2,4-DP MCPA
Absorption >83% >94%? >95%
metabolism hydroxylation
(parent and hydroxylated metabolites > 93%)
minor undeﬁned
(parent 71%, undeﬁned metabolite fraction 14%)
Elimination (urine) >80% >85% >86%
Elimination (feces) <13% <7% <7%
Half life <8 h <8 h 4e8 h
Table 3
Summary of 28d toxicity data of the two source substances MCPA and 2,4-DP and the target substance MCPP. Findings are based on the toxicological studies described in van
Ravenzwaay et al, 2005 (MCPA), California Environmental Protection Agency, 2002 (2,4-DP) and European Commission 2003 (MCPP).
MCPP 2,4DP MCPA
Dose level 50 and 400 ppm 100 or
500 ppm
2000 ppm















Increased creatinine levels; Decreased glucose
levels
Increased alanine aminotransferase activity
and magnesium levels; Decreased bilirubin,







Urinalysis Increased urobilinogen excretion (not
signiﬁcant); Increased number of degenerated
transitional epithelial cells
Increased urobilinogen excretion e e e e
Necropsy Lower absolute weights of liver,
epididymides, heart, spleen, thymus and
adrenal glands; Higher relative weights of
testes and brain; (multi)focal tubular
degeneration, occurring in single tubules of
testes (3/5)
lower absolute weights of thymus and lower
absolute and relative weights of ovaries and
adrenal glands; slightly decreased number of
hematopoietic cells was noted in the bone
marrow (2/5)










NOAEL 400 ppm Not
determined
Not determined
NOEL 50 ppm 500 ppm Not determined
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ropsy, males showed signiﬁcantly lower absolute weights of liver,
epididymides, heart, spleen, thymus and adrenal glands and
signiﬁcantly higher relative weights of testes and brain. Signiﬁ-
cantly lower absolute weights of thymus and lower absolute and
relative weights of ovaries and adrenal glands were recorded for
females. The incidence of gross organ ﬁndings did not distinguish
treated animals from controls. A slightly decreased number of he-
matopoietic cells was noted in the bone marrow of two females. A
(multi)focal tubular degeneration, occurring in single tubules, was
observed in the testes of three males.
Overall, MCPA at 2000 ppm caused a reduction in body weight,
which explains the lower absolute organ weights. Clinical chem-
istry suggests that liver and kidney are target organs at a functionallevel, but doses were not high enough to cause pathological
changes. The testes may be an additional target organ, although the
observed changes may also be related to the decreased body
weights in these young adult animals. A NOAELwas not determined
in this study.3.2. 2,4-DP (reviewed by California Environmental Protection
Agency, 2002)
Ten male and ten female Wistar rats per group received 2,4-DP
at a dietary concentration of 0, 100 or 500 ppm of 2,4-DP for 4
weeks (OECD 407 guideline study). The test substance intake cor-
responded to 9 and 42 mg/kg/day in males and 9 and 45 mg/kg/day
in females.
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treatment-related clinical signs nor effects upon mean body
weight, food consumption, hematology or clinical chemistry. Nec-
ropsy and histopathology did not reveal any treatment-related le-
sions. The NOEL (M/F) was determined to be 500 ppm.
3.3. Conclusion 28-day toxicity source substances
The NOEL for MCPA is below 170 mg/kg bw/day. At this dose
body weight development was affected, and a functional impair-
ment of the liver and the kidneywas suggested by clinical chemical/
urinalysis parameters and potentially testicular toxicity. The NOEL
for 2,4-DP is above 42mg/kg bw, a toxicity proﬁle was not obtained.
Although no deﬁnitive toxicity data for 2,4-DP were obtained in the
28-day study, there is no formal disagreement between the two
source substances. Given the similarity in structure it could be
proposed that the toxicity may be similar.
3.4. MCPP (reviewed by European commission 2012)
Ten male and femaleWistar rats were fed a diet containing 0, 50
and 400 ppmMCPP (ca. 5 mg/kg bw and 36mg/kg bw respectively).
The 28-day study (according to OECD407 guidelines) was extended
by 21 days, making the total study duration 49 days (7 weeks). Body
weights and food consumption were not affected by treatment. At
400 ppm there was a reduction in cholesterol levels in male and
female animals, as well as an increase in urea and creatinine values
in female rats. At 400 ppm increased kidney weight and increased
liver weights were seen in male and female animals. These changes
were not considered to be adverse in nature. The NOAEL was
considered to be 400 ppm, while the NOEL in this study was
50 ppm (ca. 5 mg/kg bw/day).
4. Metabolomics
4.1. Metabolome analysis
Within the context of metabolomics, metabolites are deﬁned as
small endogenous compounds such as carbohydrates, amino acids,
nucleic acids or fatty acids and their derivatives resulting from
biochemical pathways (Lindon et al., 2004, 2006). The use of sen-
sitive LC-MS and GC-MS (gas chromatography coupled with mass
spectrometry) techniques offers the possibility to detect a broad
range of such metabolites and thus increases the chance of ﬁnding
relevant biomarkers or patterns of change associated with a
biochemical effect. We have shown that metabolite proﬁling in rats
may well serve as a tool for identiﬁcation of toxicological modes of
action (Mattes et al., 2013, 2014; Kamp et al., 2012; Strauss et al.,
2009; van Ravenzwaay et al., 2007). Since 2004, BASF SE has
established a large metabolomics database (MetaMap®Tox) for
data-rich chemicals, agrochemicals and drugs.
Wistar rats were maintained in an air-conditioned room under
standardized environmental conditions. Dose levels for MCPP,
MCPA and 2,4-DP were 1000 and 2500 ppm. For each dose group
ﬁve male and ﬁve female animals were used. The common control
group consisted of 10 males and 10 females. For all compounds
tested blood samples were taken after 7, 14 and 28 days at the same
period of time in order to avoid changes related to circadian
rhythms. The study design can be best compared to an OECD 407
guideline design with two dose levels and can be easily integrated
in this type of guideline study. However, in this speciﬁc setup only
the metabolome is analyzed and no further examinations (e.g.
pathology, clinical chemistry) was conducted.
The plasma metabolome was examined by GC-MS and LC-MS/
MS techniques, as described in van Ravenzwaay et al., 2007.Brieﬂy, proteins were removed from plasma samples by precipita-
tion. Subsequently, polar and non-polar fractions were separated
for both GC-MS and LC-MS/MS analysis by adding water and a
mixture of ethanol and dichloromethane. For GC-MS analysis, the
non-polar fraction was treated with methanol under acidic condi-
tions to yield the fatty acid methyl esters derived from both free
fatty acids and hydrolyzed complex lipids. The non-polar and polar
fractions were further derivatized with O-methyl-hydroxylamine
hydrochloride and pyridine to convert oxo-groups to O-methyl-
oximes and subsequently with a silylating agent before analysis
(Roessner et al., 2000). For LC-MS analysis, both fractions were
reconstituted in appropriate solventmixtures. HPLCwas performed
by gradient elution using methanol/water/formic acid on reversed
phase separation columns. Mass spectrometric detection technol-
ogy was applied which allows target and high sensitivity MRM
(Multiple Reaction Monitoring) proﬁling in parallel to a full scan
analysis (European Patent application no.: 03711878.3; PCT/
EP2003/001274). Following comprehensive analytical validation
steps, the data for each analyte were normalized against data from
pool samples. These samples were run in parallel through the
whole process to account for process variability. For all metabolites,
changes were calculated as the ratio of the mean of metabolite
levels in individual rats in a treatment group relative to mean of
metabolite levels in rats in a matched control group (time point,
dose level, sex). The data generated were analyzed by univariate
and multivariate statistical methods and a sex and day-stratiﬁed
heteroscedastic t-test (“Welch test”) was applied to compare
treated groups with respective controls. P-values and ratios of
corresponding group medians were collected as metabolic proﬁles
and fed into the MetaMap®Tox database.
4.2. Metabolome data evaluation
4.2.1. Pattern ranking
Based on the hypothesis that chemicals or diseases that produce
a speciﬁc form of toxicity through a shared mode of action (MOA),
should produce at least a subset of speciﬁc metabolite changes
which are the same for all of these compounds, patterns of
metabolite changes associated with toxicity were established. For
the creation of such patterns, we have deﬁned speciﬁc rules (van
Ravenzwaay et al., 2014). We have set a threshold for selectivity
in such away, that compoundswhichmatch at least with 75% of the
metabolite regulations in the established patterns ﬁt to the MOA
(>75% ¼ weak match; > 90% ¼ match, see Tables 4e8). The
metabolite proﬁle of a compound under investigation (here: MCPP,
MCPA and 2,4-DP) is compared, by an automated procedure,
against all of the patterns associated with a particular MOA or
adverse outcome.
The pattern ranking for itself is a two-step process. Firstly, an
algorithm used in the database compares the metabolite proﬁle of a
compound under investigation against all of the patterns associ-
ated with a particular mode of action or adverse outcome. This
comparison yields a ranking list based on similarity of the test
compound metabolite proﬁle compared to the speciﬁc patterns in
MetaMap®Tox, using a median r-value metric. Secondly, the
metabolite changes are evaluated by an expert panel of experi-
enced toxicologists to determine what may be described as
“conﬁrmed” matches. Generally, based on the number of
commonly changed metabolites, a match requires that approx. 90%
or more of metabolites signiﬁcantly changed as deﬁned by the
pattern (weak matches: approx. 75e90%). Furthermore, the quality
and importance of the metabolite changes for a certain toxicolog-
ical mode of action are considered for this evaluation. For example,
metabolites which are based on perturbances of speciﬁc
biochemical pathways, and which can be connected to the toxicity
Table 4
Pattern ranking of MCPA demonstrated the following matches/weak matches with pre-deﬁned patterns in the database.
Table 5
Pattern ranking of 2,4-DP demonstrated the following matches/weak matches with pre-deﬁned patterns in the database.
Table 6
Pattern ranking of MCPP demonstrated the following matches/weak matches with pre-deﬁned patterns in the database.
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deﬁned so-called “anchor metabolites”. These metabolites are
essential components of the biochemical pathway related to the
mode of action, and these have to be signiﬁcantly changed in the
right direction in order to result in a matching pattern. For those
patterns for which a match (or close match) is noted, a subsequentexpert judgement of the individual metabolite regulations is
performed.
4.2.2. Proﬁle comparison
The proﬁle comparison is performed on the basis of the entire
metabolome proﬁle of a target compound, against all other
Table 7
Common patterns obtained in the metabolome analysis with the source substances MCPA and 2,4-DP and MCPP in male animals treated with 2500 ppm.
Table 8
Common patterns obtained in the metabolome analysis with the source substances MCPA and 2,4-DP and MCPP in female animals treated with 2500 ppm.
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Pearson correlations. The result is a ranking list of compoundsmost
similar to the new compound arranged by the correlation factor.
The Pearson correlation as the default option takes into account
both the overall quality of the matches of metabolite regulation, as
well as the strength of profoundly regulated metabolites. As nearly
all of the compounds in the database have a well-known toxico-
logical proﬁle, the best matches are informative of the type of
toxicity that may be expected. In order to assess the size and
relevance of a correlation coefﬁcient a reference distribution of
correlation coefﬁcients was derived by calculating all pairwise co-
efﬁcients of the whole database stratiﬁed by sex (male/female) and
dose (high/low). As each stratum comprises approximately 500
treatments (t-proﬁles) the quantiles of each reference distribution
are based on approximately 130,000 r-values/stratum. Based on
these analyses, a threshold value of 0.40 for male animals and 0.50
for female animals displays approximately the 95th percentile of all
correlation coefﬁcients obtained by the proﬁle comparison. Corre-
lation coefﬁcients above these values are considered as indicating a
clear match between two treatments and as likely to be biologically
relevant.4.2.3. Biochemical pathways
With metabolomics the regulation of several metabolites in
blood is assessed. For the establishment of the MetaMap®Toxdatabase the metabolite changes are interpreted together with
clinical pathology and histopathology data. This information can be
used to explain biochemical pathway alterations of unknown
compounds.
4.2.4. Expert judgement
Final conclusions are drawn based on a multi-step procedure.
Firstly, an inspection of all regulated metabolites is performed and
possible conclusions with respect to biochemical pathways are
drawn. Following steps are pattern ranking and proﬁle comparison.
It is essential to combine the results of all analyses before conclu-
sions are drawn. When the identiﬁed proﬁles match with the
toxicological properties of compounds which have a high rank in
the pair-wise comparison, there is reasonable certainty that a cor-
rect MOA/adverse outcome has been identiﬁed. The results of a
compound analysis are always presented to a team of experts.
4.3. Strengths and weaknesses of plasma based metabolomics
Metabolome changes are the last in line of a series of changes
caused by toxicity or the adaption of an organism to new condi-
tions. Not all DNA is transcribed into RNA, not all RNA is turned into
protein, and not all protein expressed is active. However, if this
cascade of changes does occur and e.g. more P450 enzymes are
formed, then this increased activity will affect the metabolites of a
B. van Ravenzwaay et al. / Regulatory Toxicology and Pharmacology 81 (2016) 288e304 295cell. Thus, metabolite changes are the last step before classical
toxicological observations manifest themselves.
Plasmawas selected as thematrix for analysis because all organs
exchange metabolites with the blood, and as such one matrix could
serve as amelting pot for all changes in an organism. The advantage
is that this signiﬁcantly reduces the amount of testing necessary,
the sample procedure is only minimally invasive and that animals
can be followed longitudinally over time. The disadvantage is that
for compounds with multiple organ toxicities the changes in me-
tabolites cannot be immediately allocated to an organ, and
biochemical pathways are in many cases not easy to determine. It
should also be noted that the plasma based metabolomics as pre-
sented here is not a high throughput technology. For building our
database we have selected time points (day 7, 14 and 28 of
administration) for which we assume that already a certain level of
homeostasis is achieved within the organism. The database is
limited to systemic toxicity testing and applicable for short- and
subchronic-toxicity evaluations. The obtained MOA information is
helpful to address other points such as human relevance (if known
for a particular MOA) or to identify potential effects on fertility. It is
not suitable, however, for developmental toxicity, and more subtle
forms of reproduction toxicity.
The database now contains more than 500 reference com-
pounds and a further 250 compounds with limited toxicological
data. The very high number of reference compounds has allowed us
to create about 120 patterns of metabolomic changes that can be
associated with nearly all of the classical forms of organ toxicity
observed in OECD guideline studies for systemic toxicity. Over the
last years we have compared our prediction based on metab-
olomics with that of classical pathology in the same study. Overall,
the rate of correct prediction was >80% (manuscript in prepara-
tion). In a further analysis of 122 cases, we have looked at the
relative sensitivity of metabolomics versus classical toxicology (van
Ravenzwaay et al., 2014). Again in >80% of these cases, sensitivity
was similar (i.e. we observed metabolome changes at effect levels
in the classical study and the absence of effect levels where a
NOAEL had been determined). Increased sensitivity of metab-
olomics (12% of all cases) was noted for enzyme changes (e.g. liver
enzyme induction). In the absence of further ﬁndings, such changes
are not regarded as adverse, thus largely explaining the apparent
increased sensitivity. The cases of reduced sensitivity (accounting
for 5% of all cases) can be allocated to three groups:
1. Organs for which no pattern has been established yet (i.e. rare
forms of toxicity) but for which a metabolome change is visible,
one case of sertoli-cell toxicity.
2. Organs for which no pattern has been established yet (i.e. rare
forms of toxicity) and for which a metabolome change is not
visible, one case of crystals in the urinary bladder
3. Reduced body weight during the ﬁrst week of administration
(related to initially reduced food consumption) with a subse-
quent recovery. For these studies only day 28 blood was
analyzed.
As mentioned earlier metabolite changes observed in the blood
may be associated with more than one form of organ toxicity. In
establishing selective patterns, we dissect the overall changes into
separate patterns. This is achieved by 1) using compounds with
very speciﬁc effects (single organ toxicity) and establishing pat-
terns for selective organ toxicity. In case of mixture effects, these
patterns can be subtracted from the overall changes, and the
remaining changes are then further analyzed. A further way to
obtain a selective proﬁle is to combine the evaluation for many
compounds, which share a particular form of toxicity, and to
request that only those metabolites are shown which arecommonly regulated in all compounds. If the number of com-
pounds is high enough, only the common MOA will remain.
It should be noted that the strength of changes in a particular
proﬁle cannot be immediately correlated with the strength of the
toxicity, because certain organs (e.g. liver) have a more dominating
effect on the plasma metabolome than others (e.g. lung).
5. Results of the metabolome analysis
5.1. Pattern ranking
5.1.1. Evaluation of MCPA
MCPAwas administered for 28 days to Wistar rats at dose levels
of 1000 and 2500 ppm. Blood samples were taken at day 7, 14 and
28 for metabolome analysis.
At the high dose level, body weight was signiﬁcantly decreased
in male (17%) and female (15%) animals most likely due to a
signiﬁcantly reduced food consumption of up to 45% compared to
controls in female animals and up to 21% in male animals. Neither
body weight nor food consumption was affected by the low-dose
treatment. The matches/weak matches with pre-deﬁned patterns
obtained for metabolome pattern ranking of MCPA are depicted in
Table 4.
Based on these matches, MCPA, dosed at 2500 ppm is expected
to have the liver and the kidney as its target organs. Expected MOA
of toxicity are induction of biochemical parameters related to fatty
acid metabolism, potentially resulting in peroxisome proliferation
as well as reduction in the capacity of the kidney to transport weak
organic acids. The likelihood of the latter corollary is increased
taking into account the structure of MCPA (this compound can be
considered as a weak organic acid).
At 1000 ppm, in males the liver is expected to be the target
organ, in females the kidney would be predicted to be the more
sensitive organ. A NOAEL below 1000 ppm would be expected.
Comparing these results with the available data from the 28-day
study performed with this compound shows that the predicted
MOA/target organs are in line with the toxicological results.
5.1.2. Evaluation of 2,4-DP
2,4-DPwas administered for 28 days toWistar rats at dose levels
of 1000 and 2500 ppm. Blood samples were taken at day 7, 14 and
28 for metabolome analysis.
The body weight in male animals treated with 2500 ppm of 2,4-
DP was signiﬁcantly decreased up to 13% after 28 days although
food consumption was only decreased at the beginning of the
treatment (26%). In female animals, body weight was signiﬁcantly
decreased up to 10% after 28 days of treatment although food
consumption was not affected by the treatment. Male animals
treated with the low dose of 2,4-DP showed a slight increase in
body weight due to increased food consumption, whereas body
weight and food consumption of female animals were unaffected.
The latter changes are not considered to be adverse in nature,
however. The matches/weak matches with pre-deﬁned patterns
obtained for metabolome pattern ranking of 2,4-DP are depicted in
Table 5. Based on these matches 2,4-DP when dosed at 2500 ppm is
expected to have the liver and the kidney as its target organs. Ex-
pected MOAs of toxicity are induction of biochemical parameters
related to fatty acid metabolism, resulting in peroxisome prolifer-
ation as well as reduction in the capacity of the kidney to transport
weak organic acids. 2,4-DP based on its structure can be considered
as a weak organic acid. At 1000 ppm the liver in males can be ex-
pected as a target organ.
As the 28-day toxicity study with 2,4-DP was dosed at signiﬁ-
cantly lower dose levels than those used in the metabolome study,
there is no possibility to verify the results of the metabolome
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should be noted here, however, that the predicted MOA of MCPA
and 2,4-DP are substantially similar and that body weight devel-
opment at 2500 ppm for both compounds in the metabolome
studies was reduced.
5.1.3. Evaluation of MCPP
MCPP was administered for 28 days toWistar rats at dose levels
of 1000 and 2500 ppm. Blood samples were taken at day 7, 14 and
28 for metabolome analysis.
The body weight of male animals treated with 2500 ppm MCPP
was decreased up to 12% after 28 days of treatment although food
consumption was only signiﬁcantly decreased (11%) at the begin-
ning of the treatment. Female animals showed a reduction of body
weight of up to 14% at the end of the treatment in accordancewith a
signiﬁcant reduction of food consumption of up to 31%. Male ani-
mals treated with the lower dose of MCCP showed a signiﬁcant
increase in food consumption at the end of the treatment, however
the body weight was not affected. Body weight and food con-
sumption of female animals treated with the lower dose of MCPP
were not affected by the treatment. The matches/weak matches
with pre-deﬁned patterns obtained for metabolome pattern
ranking of MCPP are depicted in Table 6. Based on these matches
MCPP when dosed at 2500 ppm is expected to have the liver and
the kidney as its target organs. Expected MOAs of toxicity are in-
duction of biochemical parameters related to fatty acidmetabolism,
possibly resulting in peroxisome proliferation as well as reduction
in the capacity of the kidney to transport weak organic acids. Based
on the chemical structure of MCPP, this compound can be consid-
ered as a weak organic acid.
As the 28-day toxicity studies with MCPP were dosed at
signiﬁcantly lower dose levels there is no possibility to exactly
verify the results of the metabolome prediction with those of the
classical 28-day toxicity study in rats. The ﬁndings observed in the
28-day study at 400 ppm (1) reduction in cholesterol and increased
liver weight suggest the liver to be a target organ, and (2) an in-
crease in urea and creatinine values and increased kidney weight
suggest the kidney to be the second target organ. This is exactly in
line with the predictions from the metabolome investigation, albeit
at higher dose levels. It should be noted here, that the predicted
MOAs of MCPP are substantially similar with those of MCPA and
2,4-DP, and that at 2500 ppm all compounds affect body weight
development in a similar way.
5.1.4. Combined metabolome evaluation
All three compounds showed a clear effect on the liver, match-
ing patterns for liver peroxisome proliferation and ﬁbrate as well as
phthalate induced liver toxicity, the MOA of these compounds be-
ing related to a lipid reducing effect, based on PPAR-alpha induction
and subsequent peroxisome proliferation (Table 7). 2,4-DP and
MCPP showed also weakmatches for liver oxidative stress, whereas
MCPA and MCPP showed a weak match indicating activation of the
liver PPAR receptor. In addition to the liver, also the kidney was
identiﬁed as a target organ. All treatments generated at least aweak
match with the pattern for the inhibition of the transport of weak
organic acids in the kidneys. MCPA and MCPP also matched with a
pattern for reduced feed consumption. Analysis of the clinical data
conﬁrmed this ﬁnding for all three substances. This also led to a
reduction of body weight of up to 17% during treatment. Overall,
the three treatments showed a good overlap regarding the toxicity
MOA patterns generated.
In female animals, the target organs were also liver and kidney,
but less pronounced compared to male animals. All three treat-
ments resulted in matches for liver peroxisome proliferation and
the inhibition of weak acid transportation in kidneys (Table 8).5.2. Proﬁle comparison
If all treatments present in MetaMap®Tox were correlated with
MCPP (more than 1800 treatments, more than 800 different sub-
stances) it correlated best with itself in a repeated study in male
animals, which was conducted to evaluate the reproducibility of
the test system. 2,4-DP is directly ranked at the second position
with a very high correlation coefﬁcient of 0.79. In female animals
MCPP correlated best with 2,4-DP with a very high correlation
coefﬁcient of 0.82. These values correspond to the 99th percentile
in males and in females of all possible rankings, clearly showing the
very high similarity between the two compounds. Although the
similarity percentile of MCPA with MCPP still is quite high (>95th
percentile), it did not rank as close as 2,4-DP did. Compoundswith a
better overall metabolome match than MCPA were ﬁbrates and
phthalates. The common denominator of these substances is the
induction of lipid metabolism and the potential to cause peroxi-
some proliferation. As this is also one of the two dominant MOAs
identiﬁed for MCPP (as well as 2,4-DP) this good match is not
surprising, but rather a conﬁrmation of the conclusions drawn from
the pattern ranking. Overall, it can be concluded that the proﬁle
comparison of the compounds is in good accordance with the
predicted toxicity proﬁles of the compounds. Proﬁle comparison
conﬁrms the indication obtained from evaluation of the metabo-
lites, that 2,4-DP is more similar to MCPP than MCPA, and thus
would be a more suitable source substance. The latter can also be
visualized by a principal component analysis depicted in Fig. 3.5.2.1. Quantitative prediction of toxicity
The results of the 90-day toxicity study with 2,4-DP are fully in
line with what could be expected based on the 28-day metabolome
analysis, and the data obtained in the 28-day study. At 2500 ppm
there were effects on body weight, and the target organs were the
liver and the kidney. As mentioned above, from a metabolomics
(biological) point of view, MCPP is more closely related to 2,4-DP
than to MCPA. Thus we would predict the same qualitative
toxicity proﬁle for MCPP as that for 2,4-DP.
The metabolome analysis can also be used to provide a
comparative estimate of the strength of the toxicity induced
treatments. There are two ways to obtain such quantitative infor-
mation. On the one hand, the strength of effect can be estimated by
the sum of the fold change values of commonly, signiﬁcantly
changedmetabolites (p < 0.05, see Table 1) and compared with that
of the same dose (2500 ppm) of the three compounds under
investigation (Table 9). This calculation was also performed for the
commonly, signiﬁcantly changed metabolites when a lower dose
(1000 ppm) was administered.
Overall, the compounds appear to be equally potent. Females
have lower values than males. There is a steep dose relationship,
and the values found at 1000 ppm are only moderately higher than
what could be expected from random change. A further way to
quantitatively compare the proﬁles of the three compounds is to
calculate the overall proﬁle strength. The overall proﬁle strength of
a “target proﬁle” is calculated as the median proﬁle P of all analytes
of target treatment:




In short, it can be described as the “rounded down average of
absolute medians of t-values”. The advantage of this second
method is that it takes all metabolites into account and is inde-
pendent on an arbitrary set p-value. Results of these calculations
are shown in Table 10. The results of the evaluation of the overall
proﬁle strength indicate that MCPP and MCPA have a similar
Fig. 3. Principle component analysis of the metabolome of MCPA, 2,4-DP and MCPP. Overall proﬁles are similar, however, subtle compound differences can be differentiated. The
metabolic proﬁle produced by MCPP is more similar to the one produced by 2,4-DP than to the metabolic changes induced by MCPA.
Table 9
Sum of the fold changes of commonly signiﬁcantly changedmetabolites (p < 0.05) at
three time points in rat plasma of four week studies with administration of
2500 ppm 2,4-DP, MCPP and MCPA and with administration of 1000 ppm of the
three compounds. For all fold changes <1.0 reciprocal values were used for calcu-
lation of the sums.
Dose 2,4-DP MCPP MCPA
Males Females Males Females Males Females
2500 ppm 292 210 292 165 320 185
1000 ppm 29 23 33 23 30 33
B. van Ravenzwaay et al. / Regulatory Toxicology and Pharmacology 81 (2016) 288e304 297strength of effect, whereas 2,4-DP is slightly weaker. The dose
response relationship is relatively steep, the values obtained for
2,4-DP are suggestive of only a moderate effect and approaching
those of control values (control values/random change values go up
to a value of ca. 0.8). The values at 1000 ppm for MCPP and MCPA
are indicative of a clear test substance related effect at this dose
level.
The overall quantitative analysis of the strength of effects in-
dicates that there are no great differences between the three
compounds. MCPP is at least as potent as 2,4-DP and possibly
slightly stronger, particularly at the lower dose level. For read
across purposes, we assume the same strength of effects at the high
dose level. We predict that the NOAEL for MCPP may be below the
one for 2,4-DP. Thus, in conclusion, we expect the 90-day toxicity of
MCPP to be similar to that of 2,4-DP, however, with potentially a
lower NOEL (comparable to that of MCPA).Table 10
Overall proﬁle strength of 2,4-DP, MCPP and MCPA for males and females at
2500 ppm and 1000 ppm.
Dose 2,4-DP MCPP MCPA
Males Females Males Females Males Females
2500 ppm 2.44 2.29 3.02 2.84 3.01 2.79
1000 ppm 1.14 1.1 1.85 1.57 1.81 1.715.3. Biochemical pathways
The magnitude of metabolic changes induced by all three sub-
stances (determined at p < 0.05) were comparable. In male animals
of the high dose groups (2500 ppm) between 35 and 43% of the
measured metabolites were signiﬁcantly changed, in females of the
mentioned dose groups 24e40%, which represents a strong effect
of the three substances on the metabolome. Especially in males, a
large subset of metabolites was regulated in common due to
treatment with the test substances (Table 11).
These included, amongst others, amino acids and a large fraction
of fatty acids, phosphatidylcholines and lysophosphatidylcholines.
In females, not as many metabolites were regulated in common by
all three treatments. Uniquely, in both sexes down-regulated me-
tabolites are long chain fatty acids (>C18), i.e. 17-
methyloctadecanoic acid and docosahexaenoic acid, whereas spe-
ciﬁcally dihomo-gamma-linolenic acid is up-regulated inmales and
females (Table 11 and Table 12). These changes are induced typi-
cally by peroxisome proliferators. It can be assumed that the
common glucuronic acid increase in plasma of male and female rats
is an effect of the inhibition of the renal excretion due to the
compounds. A unique downregulation of special amino acids (e.g.,
tryptophan, methionine, lysine and proline) are a hint of a common
inﬂuence of the compounds on the metabolism of these amino
acids. In contrast, various triacylglycerides and phosphatidylcho-
lines were up-regulated in females but down-regulated in male
animals. This contrasting sex-speciﬁc effect on lipids can be often
observed.
In Table 13 metabolites in male animals are listed that are
commonly regulated due to treatment with two of the test sub-
stances, but not the third. MCPP and 2,4-DP share more commonly
regulated metabolites, than MCPA. The same is depicted for female
animals in Table 14. The fact that there are more metabolites
commonly regulated betweenMCPP and 2,-DP than betweenMCPP
and MCPA is further evidence indicating that 2,4-DP is more suit-
able as a sources substance than MCPA for read across to the target
substance MCPP.
Table 11
Commonly regulated metabolites for all three substances in male animals treated with 2500 ppm of the test compound.
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6.1. MCPA (reviewed by JMPR, 2012, Health Canada)
In a combined subchronic toxicity and neurotoxicity study
(OECD 408 and 424 guideline, US-EPA OPTTS 870-3100 and 870-
6200 guideline), MCPA was administered to groups of 15 male and
15 female Wistar rats for 3 months at dietary concentrations of 0,
50, 500 or 2500 ppm (equivalent to doses of 0, 3, 34 or 177 mg/kg
bw per day for males and 0, 4, 42 or 188 mg/kg bw per day for
females).
At the highest dose, a signiﬁcant decrease in body weight
development was observed in both sexes (42% in males, 48% in
females), food consumption being clearly reduced particularly
during the ﬁrst 7 days of the study. At the highest dose, in both
sexes, a signiﬁcant decrease in hematological parameters (red
blood cells, hemoglobin and hematocrit), and a signiﬁcant increasein liver enzymes (alanine aminotransferase, alkaline phosphatase
and aspartate aminotransferase) were observed. Histopathology
demonstrated alterations of hepatocytes, characterized by cyto-
plasmic eosinophilia and granular cytoplasm. In addition, a higher
incidence/grading of foam cell accumulations in the lung and
myeloid atrophy of the hematopoietic marrow were seen in both
sexes. In high-dose males, a decrease in testes weights, testicular
atrophy and atrophy of the seminal vesicles and prostate, aspermia
or oligospermia in the epididymides were observed. For the
neurotoxicity evaluation, functional observational battery and
motor activity assessments were performed on 10 animals per sex
per group prior to the treatment and on treatment days 22, 50 and
85. Effects observed at 2500 ppm were a decreased value of hin-
dlimb grip strength in females on day 85, decreased foot splay test
values (p < 0.02) in males on day 22 and reduced values (p < 0.02)
of forelimb grip strength in males on day 50. The results of the FOB
as well as those on testicular development need to be assessed
Table 12
Commonly regulated metabolites for all three substances in female animals treated with 2500 ppm of the test compound.
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dose was clearly exceeded, both in terms of bodyweight develop-
ment as well as in terms of being beyond the maximum capacity of
renal excretion. Therefore, they may not be selective in nature No
signiﬁcant treatment-related changes were seen at the two lowest
doses. The NOAEL was at 500 ppm.
In a second study MCPAwas administered toWistar rats (15 per
sex per dose) at dietary concentrations of 0, 50, 150 or 450 ppm
(equivalent to doses of 0, 3.6, 10.9 and 32.6 mg/kg bw per day for
males and 0, 4.0, 12.1 and 35.8 mg/kg bw per day for females).
At 450 ppm, an increase in creatinine values in the plasma of
females was observed. At the same level, decreases in cholesterol
and calcium values in the males were observed. Also, an increase in
absolute and relative kidney weights in males was observed. At
150 ppm, increased absolute kidney weights (108% of controls)
were noted (p < 0.05). No changes were observed at the lowest
level (50 ppm). In the absence of histopathological changes, and
clinical-pathological changes at 150 ppm, this dose could be
regarded as a NOAEL.
The ﬁrst study demonstrates that at 2500 ppm body weight
development is severely affected. Target organs are the liver, as
evidenced by clinical chemistry and histopathology. A second
target is the hematopoietic system, demonstrated by reduced red
blood cell values, probably caused by an atrophy of the hemato-
poietic bone marrow cells. Effects noted in the functional obser-
vation battery and the effects on themale reproductive systemmay
have been secondary to the body weight effects. The second study,
performed at lower dose levels primarily identiﬁes the kidney as a
target organ, as evidenced by increased kidney weights, urinary
bilirubin, urinary crystals and altered pH values. The ﬁrst study
indicates a NOAEL at 500 ppm, whereas the second study suggest
the NOAEL to be at 150 ppm.6.2. 2,4-DP (reviewed by California Environmental Protection
Agency, 2002)
15 male and 15 female Wistar rats per group were dosed in the
diet with 0,100, 500, 2000 (males only) or 3000 (females only) ppm
of 2,4-DP for 13 weeks in an OECD 408 like guideline study, cor-
responding to a test substance intake of 0, 7, 35, 144 mg/kg/day for
males and 0, 8, 42, 245 mg/kg/day for females.
No mortality resulted from the treatment. No treatment-related
signs were noted in the general clinical observations. The mean
body weight of the 2000 ppm males was less than that of the
controls during the ﬁrst 8 weeks of the study (p < 0.05 or 0.01).
Mean food consumption for these animals was less than that of the
controls for the ﬁrst 2 weeks of the study (p < 0.05 or 0.01). The
mean body weight and food consumption values for the 3000 ppm
females were lower than those of the control throughout the study
(p < 0.01). In contrast, mean water consumption for the 2000 ppm
males and the 3000 ppm females was greater than that of the
controls throughout the study (p < 0.01). Only the fore and hind
limb grip strength parameters were apparently affected in the
functional observational battery. The mean values for these treated
animals were all within the historical control range. Mean motor
activity was reduced for the 3000 ppm females at the 5-day time
point. Otherwise, no other apparent treatment-related effect on
activity was noted. For hematology, red blood cells, hemoglobin,
and hematocrit, values were less than those of the controls for both
high dose males and females. Among the clinical chemistry pa-
rameters, mean serum alkaline phosphatase activity was increased
for the 2000 ppm males and the 3000 ppm females. In addition,
mean globulin, triglycerides, and cholesterol values were less than
those of the controls for the high dose males and females. In the
urinalysis results, speciﬁc gravity was lower and the presence of
erythrocytes and bacteria was greater for the high dose females. No
gross lesions were noted in the necropsy examination. Absolute
Table 13
Differentially regulatedmetabolites in phenoxy test substances inmale animals. Listed are all metabolites whichwere commonly regulated in two of the test substances (MCPP
and 2,4-DP (a); MCPP and MCPA (b)), but differentially regulated in the third substance.
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Relative liver and kidney weights were greater for both high dose
males and females. No lesions were noted in the nervous tissue. For
the other animals, a decrease in fat storage and an increase in
incidence and severity of cytoplasmic eosinophilia and granular
cytoplasm in the liver was noted for the high dose males and fe-
males. No observed adverse effect level was 500 ppm.
In a second study ten Wistar rats/sex/group were treated in the
diet with 0, 100, 500 or 2500 ppm of 2,4-DP for 3 months, corre-
sponding to a test substance intake of 0, 7.2, 36.7, 193 mg/kg/day
(males), 0, 8.3, 41.4 and 208 mg/kg/day (females).
The mean body weights for the males and females in the
2500 ppm treatment groupwere 8.1 and 8.4% less than those of the
control, respectively, at the end of the treatment. Water con-
sumption was markedly increased for both sexes in the high dose
group. In the hematology evaluation, mean red blood cell count,
mean hemoglobin concentration and mean hematocrit were lower
than the controls for both the males and the females in the
2500 ppm group. In the clinical chemistry, the 2500 ppm group had
higher mean alanine aminotransferase, alkaline phosphatase, urea,
creatinine and total bilirubin values than those of the control. The
mean globulin (both sexes), triglyceride (males) and cholesterol
(males) concentrations for this group were lower than those of the
control. The mean absolute liver weights for both sexes in the
2500 ppm group were greater than those of the control. The mean
relative weights for the kidneys of the 500 and 2500 ppm males
and the 2500 ppm females were greater than those of the control.Peripheral fatty inﬁltration of the liver was lacking in the high dose
animals. The no observed adverse effect level was 500 ppm.7. Conclusion 90-day toxicity
The two 90-day studies demonstrate reduced body weight
development at dose levels 2000/2500 ppm for males and 2500/
3000 ppm for females. At these dose levels a reduction of red blood
cells parameters is observed. Clinical-chemical investigations
demonstrate an effect on the liver (increased alanine aminotrans-
ferase and alkaline phosphatase activity as well as reduced glob-
ulin, triglyceride and cholesterol values). Clinical chemistry and
urinalysis also point to the kidney as a target organ, as evidenced by
increased urea and creatinine values as well as reduced speciﬁc
urine gravity and possibly an increased presence of erythrocytes
and bacteria. Pathological investigations conﬁrmed the liver and
kidney as target organs based on increased organ weight and the
absence of peripheral fatty inﬁltration of the liver. The NOAEL in
both studies was 500 ppm.7.1. MCPP (reviewed by California Environmental Protection
Agency, 1999)
MCPP was admixed to the feed at concentrations of 0, 75, 500,
2500 (males only) or 3000 (females only) ppm (corresponding to 0,
5, 35, or 189 mg/kg/day, respectively, for males and 0, 6, 41, or
240 mg/kg/day, respectively, for females) and fed to 15 Wistar rats
Table 14
Differentially regulated metabolites in phenoxy test substances in female animals. Listed are all metabolites which were commonly regulated in two of the test substances
(MCPP and 2,4-DP (a); MCPP and MCPA (b)), but differentially regulated in the third substance.
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No animals died and no clinical signs were observed. Treatment-
related decreased mean body weight, decreased mean food con-
sumption, and increased mean water consumption were observed
in males at 2500 ppm and in females at 3000 ppm. Treatment-
related decreased mean red blood cell, hemoglobin, and hemato-
crit levels in males at 500 and 2500 ppm and in females at
3000 ppm were observed. Treatment-related increases in alkaline
phosphatase in both sexes, alanine aminotransferase in females,
urea in both sexes, and creatinine in males were observed at
2500 ppm. A treatment-related increase in transitional epithelial
cells in the urine was observed in males at 2500 ppm. Treatment-
related increases in mean relative liver weights in both sexes at
the high dose level and in mean relative kidney weights in bothsexes at 500 ppm and the high dose level were observed. Macro-
scopic examination revealed treatment-related discoloration of the
adrenal glands in both sexes at the high dose level. Microscopic
examination revealed a dose-related decrease in fat storage in the
liver in males at 500 and 2500 ppm and in females at 3000 ppm,
and treatment-related bile duct proliferation, severe cytoplasmic
eosinophilia of hepatocytes, hepatocytes with granular cytoplasm
(moderate to severe), and lipid storage in the adrenal cortex were
observed in both sexes at the high dose level. No treatment-related
effects were observed during functional observation battery and
motor activity assessments. No neurotoxic effects were observed at
gross necropsy or microscopic examination. The NOEL was 75 ppm.
The US-EPA considers the NOAEL to be 500 ppm.
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The metabolome evaluation of the source substances indicate
liver and kidney as the target organs. Themetabolome evaluation of
the target substance provides the same information. The metab-
olome proﬁle associated with the liver indicates a lipid reducing
activity, comparable with the one induced by peroxisome pro-
liferators. This is fully in line with investigations performed already
decades ago (Vainio et al., 1983). The identiﬁcation of the kidney as
a target organ is particularly important because a hallmark of the
phenoxy herbicides is the saturation of renal excretion and reab-
sorption causing a rise in compound blood levels associated with
the onset of toxicity (Timchalk, 2004; van Ravenzwaay et al., 2004).
The metabolome pattern observed for renal toxicity is that associ-
ated with inhibitors of weak organic acid excretion and with
reference compounds such as probenecid (Wang et al., 2014).
The overall comparison of the metabolome data indicate that
2,4-DP is the best source substance. Using the information of the
90-day study of this compound, it would have been predicted that
MCPP would have shown decreased food consumption and body
weight gain at 2500 ppm. The target organs are the liver (weight
increase and clinical-pathology changes), as well as the kidney
(weight increase and clinical-pathology changes). The metabolome
analysis did not predict effects on the red blood cells as observed in
the 90-day studies. It should be noted, however, that in the 28 day
study with MCPA at a dose level similar to the one used in the 90
day study, also no effects on red blood cells were noticed. Therefore,
the lack of identiﬁcation of this effect in the metabolome in-
vestigationsmay be related to the fact that the effect simply had not
manifested itself yet. The type of red blood cell changes observed
with the three phenoxy-herbicides after the 90-day treatment
suggests that this is related to a reduction in bone marrow activity.
An in depth analysis of the metabolome of the three compounds
did reveal changes in a few metabolites which are consistently
associated with anemia (reduced cytosine and deoxyribonucleic
acids) in several patterns for anemia. Additionally, therewas aweak
match with a pattern indirectly associated with reduced red blood
cell values. These changes, however, were not sufﬁcient to call this a
match. Based on the results of the 90-day study with 2,4-DP for
comparison a moderate reduction of red-blood cell parameters
would, however, be expected at 2500 ppm also for MCPP. The NOEL
would have been expected to be below the value of 2,4-DP, i.e. <
500 ppm and more likely in the range of that of MCPA, i.e. at least
150 ppm.
From a qualitative point of view, these predictions are very
similar to the results of the actual 90-day study in rats performed
with the target substance (reduced food consumption and body
weight gain, target organs: liver and kidney e weight increases
with concomitant clinical-pathology changes, reduced red blood
cells values). From a quantitative point of view the predicted NOEL
of 150 ppm for MCPP is in the range of that of the actual study
(NOEL 75 ppm, NOAEL below 500 ppm). Thus, the 90-day rat
toxicity study of the target substance (MCPP) could have been
waived and substituted by the 90-day results of 2,4-DP. The NOAEL
of MCPP would have been correctly assessed as < 500 ppm, and
using MCPA's 90 day study (second source compound) values as at
least 150 ppm.
This case study was presented at ECHA's workshop on New
Approach Methodologies in Regulatory Sciences held in Helsinki,
19e20 April 2016. An integral part of presenting a read-across case
is the compliance with the RAAF (read across assessment frame-
work, see http://echa.europa.eu/documents/10162/13628/raaf_en.
pdf). For this case study, the respective tables were prepared and
shown here as supplementary material. One of the main points of
discussion of this case study was the prediction of “negatives” forendpoints. Acknowledging that the prediction of absence of an
effect always is challenging, some points can be made. Importantly,
conclusions are drawn from a multi-angel perspective. Firstly, we
identify if there are matches between the ﬁxed metabolite patterns
established with reference compounds, grouped by particular
toxicological effects (MoA), and the substance investigated.
Currently, we established about 120 individual patterns to which
such a comparison is made. Then we compare the overall metab-
olome proﬁle of the substance investigated with the complete
proﬁles of all other compounds and rank these according to best
matches. Finally, we evaluate the strength of the total proﬁle. A
compound is considered “negative” if it does not have moderate e
good matches with the ﬁxed patterns, if the association of the
overall proﬁle with any of the other overall proﬁles is low (corre-
lation coefﬁcient < 0.5), and if the strength of the pattern is in the
range of control values. A further indication of the sensitivity of
metabolomics versus classical toxicology comes from a comparison
between the two.We compared the outcome of classical toxicology
(with respect to NOEL and LOEL) for > 100 compounds with that of
metabolomics, according to the above mentioned criteria, and
noted that the sensitivity of both analysis is generally quite similar
(van Ravenzwaay et al., 2014).
The workshop participants accepted the presented case study as
scientiﬁcally valid and as a good example how new technologies
can help to substantiate claims of substantial similarity between
chemicals. A number of issues were raised which merit to be pre-
sented here.
(1) The presented source substances clearly lack one chemical,
i.e. 2,4-dichlorophenoxy acetic acid (2,4-D). This compound
was not included because the appropriate metabolome data
were not available. It should however also be noted that 2,4-
D is chemically “least” comparable with the target substance.
Nevertheless, the toxicity of 2,4-D is not dissimilar to that of
MCPP; i.e. dominated by liver and kidney toxicity, changes in
red blood cell parameters (FAO, 1996).
(2) It was assumed that all impurities of the source and target
compounds were known and that their presence was not
relevant for the ﬁnal outcome of the toxicity assessment.
Given that all compounds used for this case study are
registered agrochemicals, with known impurities this was
not considered a problem.
(3) Transparency of the process how to derive conclusions from
themetabolome analysis is key to understanding its outcome
and to build trust.
(4) A framework for data capture and storage in a GLP (like)
fashion and a consistent way to interpret such data would
also help to increase applicability of new technologies. The
latter is indeed a general issue and currently a topic for which
ECETOC is organizing a workshop. For the metabolomics
work presented here data the rules for data interpretation
have been described extensively in (van Ravenzwaay et al.,
2015).
(5) The sensitivity and ability of metabolomics to detect changes,
and the ability to demonstrate the absence of an effect is the
most important factor to rely on this technology for predic-
tion of effects and determination of a no observed effect
level. Since 2008 BASF has used this technology for early
prediction of toxicological effects, and within the context of
studies performed under REACH a comparison of prediction
and real study outcome was possible. From the analysis of
these data it can be concluded that metabolomics is as sen-
sitive as a guideline toxicological study (van Ravenzwaay
et al., 2014). The rate of correct prediction of effects from
compounds with an unknown toxicological proﬁle was 83%,
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(manuscript in preparation).
‘Omics technologies have the advantage that they can be easily
combined with the standard guideline studies. In our case we have
used the 28-day (OECD 407) guideline study to obtain 0.2 ml of
plasma used for metabolome investigations. This procedure does
not interfere with the outcome of the study and it is conceivable
that other technologies, e.g. transcriptomics, could also be com-
bined with regulatory OECD studies without compromising their
validity. The combination of classical observations, including full
pathology, and the mechanistic information provided by e.g.
metabolomics, provides an ideal basis for comparison of com-
pounds. Within the MetaMap®Tox system that we use we obtain
the comparison of a selected compound with all other compounds
(currently ca. 800) based on their metabolomic proﬁle within a few
seconds. For large numbers of chemicals rapid information on po-
tential biological similarity is a great advantage to start a more
thorough evaluation of toxicological similarities. The omics infor-
mation, together with the evaluation of the classical toxicological
parameters from the 28-day study, then forms the basis of a sub-
stantiated claim to waive the performance of the 90-day study for
the selected compound, if the reference compound(s) are/is
convincingly similar. The data-base used to prepare the case study
is at this time only suitable for systemic toxicity (i.e. predicting the
toxicity of compounds for short-term to subchronic administration
periods. It is not suitable for reproduction toxicity as we have not
gathered metabolome proﬁles for this end-point. It may be quite
suitable to investigate maternal toxicity or effects on fertility in
parental animals. Wether this technology could also be used to
assess embryo-toxicity or effects on the next generation is an open
question.
Read across is andwill remain themost important tool to reduce
animal testing while providing risk assessors with the necessary
information to do their work. Ball et al. (2016) note that clear focal
points of work to enhance the good use of the read across concept
are amongst others, to identify best practices for using biological
proﬁling/bioinformatics tools to support establishing similarity of
source and target chemicals in read-across. Failure to derive some
best practices for their use will likely lead to signiﬁcant uncertainty
into how to use these tools effectively and also create some
mistrust in the data where they are not used appropriately. Here
were demonstrate that data from new technologies can help to
increase the quality of read across cases and should enhance the
likelihood of providing successful cases to the regulatory author-
ities. It should be noted, however, that in the present study target
and source substances were structurally very similar, as this was a
prerequisite to serve as a case study within the RAAF context. The
great upside potential of such new technologies could be that they
do not necessarily have to rely on an estimate of chemical simi-
larity, but rather provide a biological foundation for similarity. We
have referred to this concept earlier as “going from QSAR to QBAR”
(quantitative biological activity relationship) (van Ravenzwaay
et al., 2012). Such a concept would signiﬁcantly enlarge the possi-
bilities for read-across cases, while reducing the risk of incorrect
read across proposals because occasionally small changes in
chemical structures can have profound toxicological consequences.
Further case studies are needed to demonstrate that this potential
can indeed come to fruition, ideally also using other ‘omics
technologies.
A further, and far more signiﬁcant step towards the reduction of
animal testing and provision of mechanistic information would be
to perform metabolomics studies in vitro. This can indeed be done
in vitro, and we have established a system for the identiﬁcation of
liver toxicity modes of action as well as cell energy metabolism(Balcke et al., 2011; Bordag et al., 2016). It should be noted, however,
that the experimental set-up and establishment of a robust and
reproducible test system is time consuming. Only when this is
achieved can the development of a database with reference com-
pounds be started. This process then has to be repeated for at least
all major organs investigated in regulatory toxicity studies. This is
achievable, but requires stamina, patience and a lot of commitment.
9. Disclaimer
This case study has been designed to illustrate speciﬁc issues
associated with read-across and stimulate discussion on the topic.
It is not intended to be related to any currently ongoing regulatory
discussions on this group of compounds. The background docu-
ment has been prepared to facilitate the discussion at the Topical
Scientiﬁc Workshop and does not necessarily represent ECHA's
position.
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